RHB-104 is a potentially groundbreaking, proprietary antibiotic combination therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. The three antibiotics are rifabutin, clofazimine, and clarithromycin. Crohn’s disease is an inflammatory disease of the gastrointestinal system with significant unmet needs.
The inflammation caused by Crohn's disease can lead to abdominal pain, severe diarrhea, rectal bleeding, weight loss, malnutrition, fever and other symptoms, the range and severity of which vary. Current therapies like steroids, ASA and biologics target symptomatic relief, are widely considered to be of limited efficacy in the long term and are associated with numerous side effects. The development of RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium…
